# A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)

> **NCT02292537** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 126 (actual)

## Conditions studied

- Spinal Muscular Atrophy

## Interventions

- **DRUG:** Nusinersen
- **PROCEDURE:** Sham procedure

## Key facts

- **NCT ID:** NCT02292537
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-24
- **Primary completion:** 2017-02-20
- **Final completion:** 2017-02-20
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2021-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02292537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02292537, "A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT02292537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*